Malady Kyle 4

What Happened

• Kyle Malady, EVP and Group CEO–VZ Business at Verizon (VZ), was granted 120.397 phantom shares (derivative award) on 2026-03-12. The filing reports an acquisition price/value of $14.44 per unit, totaling $1,739. This was an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-12; Filing date: 2026-03-13 (appears timely).
• Award: 120.397 phantom shares at $14.44 each; total reported value $1,739.
• Nature of award: Cash‑settled phantom stock (derivative), not actual common shares.
• Shares owned after transaction: Not specified in the provided data.
• Footnotes: F1 — each phantom share is the economic equivalent of a portion of one common share and is settled in cash under the deferred compensation plan; payable upon events chosen by the reporting person. F2 — includes phantom stock acquired through dividend reinvestment.
• Transaction code: A (Grant/Award).

Context

• This was a deferred-compensation award (phantom stock) that provides cash value tied to Verizon common stock performance; it does not transfer voting rights or deliver actual shares until settlement.
• Such grants are routine compensation for executives and do not, by themselves, indicate a buy/sell decision in the open market.